Nuvalent Inc (NUVL) is the lead sponsor of 4 active clinical trials listed on ClinicalTrials.gov[4], including 1 Phase 3[1], 2 Phase 2[2], 3 Phase 1[3].
Trial NCT06765109[5] evaluates Neladalkib (NVL-655) in Non-small Cell Lung Cancer with a target enrollment of 450 participants.
NUVL has 7 Form 4 insider filings recorded at the SEC in the past 30 days[6].